European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Glaxosmithkline Intellectual Property Ltd., Stevenage

Watch
Glaxosmithkline Intellectual Property Ltd.

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Glaxosmithkline Intellectual Property Ltd.

Identification

Chp
Companies House 08283186
Lei
549300X3MLVYJEQN4J15

Address

Gunnels Wood Road, Gsk Medicines Research Centre, Stevenage SG1 2NY, United Kingdom
980 Great West Road Brentford Middlesex, United Kingdom
Gsk Medicines Research Centre Gunnels Wood Road Stevenage, United Kingdom

Corporate purpose

64.20/9
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Total assets

For this company, Total assets numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
5Director
2Director
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Taxes
Tax ratio
Receivables
Liabilities
Trademarks
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

24 Aug 2026 also 08/09/2025, 02/10/2024, 26/09/2023, 23/09/2022, 20/09/2021, 24/09/2020, 11/09/2019, 03/12/2018
Confirmation statement made with no updates
20 Aug 2026
Annual report for the year ending 31/12/2025
Year 2025 in Euipotm
11 wordmarks: BYVIG , CAZNORA, CHLORNEMA, ETEBEDE, GREDERA, ODELVIE, OMFANATE, PARVUGEL, SOLDEO, UMBIPRO , UMBRASIA
15 Aug 2025
Annual report for the year ending 31/12/2024
31 Jul 2025
Director's details changed for Edinburgh Pharmaceutical Industries Limited · Secretary's details changed for Edinburgh …
15 Jul 2025
Director: Anna M. H. Fent
9 Jul 2025
No longer Director: Jemma-L. Reynolds
27 Sept 2024
Director: C. Barcelo Igles
20 Sept 2024
Director's details changed for Mrs Demet Gurunlu Russ
17 Sept 2024
Director's details changed for Mr Graham Paul Rivers · Director's details changed for Mrs Jemma-Louise Reynolds …
14 Aug 2024
Annual report for the year ending 31/12/2023
14 Aug 2024
Patent: Method for controlling antibody glycosylation profile
31 Jul 2024
No longer Director: Gregory M. Reinaud
18 Jul 2024
Address
11 Jul 2024
Appointment of Mrs Demet Gurunlu Russ as a director
5 Jul 2024
No longer Director: Jill Dawn Anderson
17 May 2024
Patent: New use of anti-Blys antibodies
15 Apr 2024
Director: Jemma-L. Reynolds
2 Feb 2024
Director: Gregory M. Reinaud
20 Sept 2023
No longer Director: Ziba Shamsi
2 Sept 2023
Annual report for the year ending 31/12/2022
16 Aug 2023
Companies House - Filing
2 Aug 2023
Director: Graham Paul Rivers
20 Jul 2023
No longer Director: James R. Wheatcroft
9 Jun 2023
Address
6 Jun 2023
Address
3 Mar 2023
Director: Jill Dawn Anderson
2 Mar 2023
No longer Director: Jerome Andries
3 Nov 2022
Director: Ziba Shamsi
2 Nov 2022
Termination of appointment of Kate Sophie Priestman as a director
15 Aug 2022
Annual report for the year ending 31/12/2021
20 Jul 2022
Patent: Belimumab Formulation
15 Jun 2022
Patent: Anti-Baff Antibodies for USE in a Method of Treatment of Long Covid and/or Post-Acute Sequelae Sars-COV-2 Infection (Pasc)
9 Mar 2022
Wordmark: “THE US IN LUPUS“
9 Mar 2022
Figurative mark
4 Oct 2021
Annual report for the year ending 31/12/2020
19 Oct 2020
Annual report for the year ending 31/12/2019
2 Apr 2020
Patent: Scheme for the treatment of Neisseria gonorrhoeae infection with gepotidacin
24 Sept 2019
Annual report for the year ending 31/12/2018
3 Sept 2019
Director: James R. Wheatcroft
7 May 2019
No longer Director: Simon Paul Dingemans
Year 2018 in Euipotm
6 wordmarks: PATERMA, PATORMLA, PETORMA, PITORMA, VARSIMLA, VELARBA
5 Oct 2018
Annual report for the year ending 31/12/2017
30 Jan 2018
Director's details changed for Mr Jerome Charles Maurice Andries
17 Nov 2017
Director: Jerome Andries
16 Nov 2017
No longer Director: Luigi F. la Corte
28 Sept 2017
Annual report for the year ending 31/12/2016
7 Jan 2017
Appointment of Kate Sophie Priestman as a director
17 Nov 2016
Confirmation statement made with updates
2 Nov 2016
No longer Director (1)
14 Oct 2016
Patent: Therapeutic Regimens for Treating Psoriatic Arthritis with an Anti-CCL20 Antibody
28 Sept 2016 also 24/09/2015, 16/08/2014
Full accounts made up to 2015-12-31
21 Sept 2016
Patent: Dosing schedule for the combination of anti-CD20 and anti-BlyS antibodies
26 Apr 2016
Resolution of adoption of Articles of Association (ADOPT ARTICLES)
8 Feb 2016
No longer Director (1)
14 Dec 2015
Capital: £300.00
6 Oct 2015
Patent
30 Sept 2015
Patent: Novel compounds
15 May 2015
Director: Luigi F. la Corte
15 May 2015
Patent: Belimumab formulation
8 Dec 2014
Capital: £300.00
28 Oct 2014
Particulars of variation of rights attached to shares · Change of share class name or designation
Year 2014 in Euipotm
8 wordmarks: BYVIG , CAZNORA, CHLORNEMA, ETEBEDE, GREDERA, OMFANATE, PARVUGEL, UMBRASIA
14 Oct 2014
Patent: Indoline Derivatives AS Inhibitors of Perk
17 Sept 2014
Particulars of variation of rights attached to shares · Change of share class name or designation …
3 Sept 2014
Patent: Pharmaceutical Compositions and Methods of Making Same
7 Jul 2014
Previous accounting period extended from 2013-11-30 to 2013-12-31
19 Dec 2013
Capital: £300.00
14 Oct 2013 also 24/01/2013
Statement of capital following an allotment of shares
17 May 2013
Director (1)
1 May 2013
Director: Adam Walker
6 Nov 2012
Reg­is­tra­tion: 06/11/2012 · Director (2) · Director: Edinburgh Pharmaceutical Industries Ltd., Glaxo Group Ltd. · Secretary: Edinburgh Pharmaceutical Industries Ltd
There are no publications matching your search.

Mentions

13 Sept 2023 in Ler
Direct parent
13 Sept 2023 in Ler
Ultimate parent
30 Apr 2021 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.